Relation key facts
as of Oct 2026- Provider of a biotechnology platform intended to develop medicines for diseases with significant unmet needs.
- Relation is valued at approximately $124.7M as of Oct 2026 (last reported valuation).
- It has raised $113.4M; the latest was Later Stage VC ($55.0M) in Dec 2025.
- Notable investors include Khosla Ventures, Tech Nation Group, DCVC, Realm Capital Ventures, Raptor Group — 20 tracked in total.
- Status: Privately Held (backing).
Relation's last reported valuation, Jan 2024. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Relation: the Monday email on marks, rounds and moves
Relation funding rounds
No funding rounds for Relation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Relation
20+Relation valuation
Relation's last reported valuation was $125 million in Jan 2024. No priced round, secondary trade or fund mark has surfaced since.
Relation investors
20 investors are on record for Relation, including Khosla Ventures, Tech Nation Group, DCVC and Realm Capital Ventures. By type, the record holds 11 venture capital firms.
About Relation
Provider of a biotechnology platform intended to develop medicines for diseases with significant unmet needs. The company offers an innovative Lab-in-the-Loop platform that integrates human genetics, single-cell multi-omics, functional assays, and machine learning, enabling the discovery of novel disease interventions directly from human tissue.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 110
- Website
- relationrx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.